Business
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed a non-binding letter of intent (LOI) establishing an exclusive negotiation framework for the potential commercialization of its sublingual cladribine oral thin film (ODF) product within one or more member states of the Eurasian Patent Organization (EAPO).","length":523,"tagName":"p"},{"type":"text","content":"The LOI outlines a structured pathway toward a potential regional licensing arrangement and follows recent patent grants and decisions covering BioNxt's proprietary cladribine ODF technology in both the Eurasian region and Europe, significantly strengthening the Company's global intellectual property position.","length":319,"tagName":"p"},{"type":"text","content":"Structured Commercialization Pathway","length":36,"tagName":"p"},{"type":"text","content":"The signed LOI represents a significant step toward regional market entry and outlines a defined pathway toward a potential definitive licensing agreement.","length":155,"tagName":"p"},{"type":"text","content":"The contemplated collaboration framework includes potential regional licensing rights, defined exclusivity during the negotiation period, and financial terms structured around upfront payments, royalties, and revenue sharing. The framework also anticipates collaboration across regulatory strategy, manufacturing coordination, quality control, and commercialization planning within the defined territory.","length":404,"tagName":"p"},{"type":"text","content":"Under the LOI, the parties have agreed to negotiate exclusively for a period of 60 days while working toward finalizing a definitive commercial agreement. While the LOI is non-binding with respect to the final transaction, it reflects the parties' mutual intent to advance commercialization discussions in the region supported by BioNxt's expanding intellectual property footprint and differentiated drug delivery platform.","length":431,"tagName":"p"},{"type":"text","content":""We believe this strategic agreement marks an important milestone in the commercialization of our cladribine ODF program," said Hugh Rogers, CEO and Director...